Aptargroup Stock Price, News & Analysis

AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has declared a quarterly cash dividend of $0.45 per share. The dividend will be paid on August 14, 2025 to stockholders of record as of July 24, 2025.

Additionally, the company announced it will hold a conference call on August 1, 2025 at 8:00 a.m. Central Time to discuss Q2 2025 results. The call will be available via webcast on Aptar's Investors page.

AptarGroup (NYSE:ATR) has unveiled a groundbreaking dual-active material science technology that simultaneously controls moisture and oxygen for pharmaceutical products. This innovative solution extends their 3-Phase Activ-Polymer™ technology to protect sensitive oral solid dose drugs, medical devices, and delivery systems.

The technology represents a significant advancement in pharmaceutical protection, particularly beneficial for GLP-1 medications and various medical devices. It can be customized for different product formats and development stages while helping companies meet ICH stability requirements. Aptar also offers complementary elastomeric components for GLP-1 drug products and integrated digital patient services.

AptarGroup (NYSE:ATR), a leader in drug and consumer product dosing and dispensing technologies, has been recognized as one of TIME's World's Most Sustainable Companies 2025, ranking 244 out of 500 global companies. This marks their second consecutive year on the list.

The company has demonstrated significant sustainability achievements, including maintaining a Platinum level rating from EcoVadis for five consecutive years, placing them in the top 1% of rated companies. Notable metrics include 97.5% renewable global electricity usage and 86% of operational waste avoiding landfill. Aptar has also secured renewable supply agreements in Europe and North America while partnering with organizations like the Ellen MacArthur Foundation to advance sustainability initiatives.

AptarGroup (NYSE: ATR), a leading provider of drug and consumer product dosing, dispensing and protection technologies, has announced its participation in two major investor conferences. The company's President and CEO Stephan Tanda, along with Executive Vice President and CFO Vanessa Kanu, will present at the William Blair 45th Annual Growth Stock Conference in Chicago on June 3, 2025, at 9:40 a.m. ET. The following day, June 4, they will present at the Jefferies Global Healthcare Conference at 2:00 p.m. ET. Both presentations will be accessible via live audio webcast through the Investors section of Aptar's website.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing and dispensing technologies, has released its 2024 Corporate Sustainability Report. The report showcases progress across three key pillars: Care, Collaboration, and Circularity. Key achievements include: • 97.5% of electricity sourced from renewables • 86% of operational waste avoided landfill disposal • 60% of sites earned Landfill Free Certification The company partnered with organizations like Ellen MacArthur Foundation and World Business Council for Sustainable Development to advance circular solutions. Aptar's sustainability initiatives focus on increasing recycled resin content and developing recyclable, reusable, or compostable solutions across their product lines. The report, prepared under GRI Standards, received external assurance for its emissions reporting from SGS do Brasil Ltda.

AptarGroup (NYSE:ATR) reported Q1 2025 results with reported sales of $887 million, down 3% year-over-year, and net income of $79 million, a 5% decrease. Core sales remained flat while adjusted EBITDA increased 3% to $183 million. The company achieved an adjusted EBITDA margin of 20.7%, expanding 120 basis points. Adjusted EPS was $1.20, which would have shown a 5% increase excluding currency effects and tax rate changes. Notably, Pharma segment showed strength with 2% growth in proprietary drug delivery systems sales. The company returned $110 million to shareholders, including $80 million in share repurchases. By segment, Aptar Pharma's core sales grew 3%, while Beauty and Closures segments declined 3% and 2% respectively. Looking ahead, Aptar expects Q2 2025 adjusted EPS of $1.56-$1.64.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing, dispensing and protection technologies, has announced a quarterly cash dividend of $0.45 per share. The dividend will be paid on May 22, 2025, to stockholders of record as of May 1, 2025.

The company has also scheduled a conference call on May 2, 2025 at 8:00 a.m. Central Time to discuss their first quarter 2025 results. The hour-long call will be available via live webcast on the Investors page at www.aptar.com, with a replay option accessible afterward.

AptarGroup (NYSE: ATR) has announced the launch of a clinical validation study for its SmartTrack™ platform, developed by its drug services company Nanopharm. The platform aims to reduce the need for clinical studies in generic drug product approvals by accurately predicting clinical outcomes for pressurized metered-dose inhalers (pMDI).

The study, scheduled to begin in Q2 2025, will involve radio-labelling three different commercial pMDI drug products and imaging regional lung deposition. The results will be compared with computational fluid dynamic simulations in collaboration with Fluidda, Medimprove, and i2c Pharmaceutical Services.

Upon completion by the end of 2025, the study data will be submitted to the U.S. FDA as one of the first Model Master Files (MMF). If validated, SmartTrack™ could accelerate approvals for generic inhaled medicines and support various programs, including pMDI reformulation with lower global warming potential propellants.

AptarGroup (NYSE: ATR), a leader in drug and consumer product dosing and dispensing technologies, has achieved the EcoVadis Platinum rating for the fifth consecutive year, placing it in the top 1% of over 150,000 rated companies across all industries.

The EcoVadis assessment evaluates performance across environment, labor and human rights, ethics, and sustainable procurement. Aptar utilizes EcoVadis for its Supplier Screening Program to integrate social and environmental screenings into purchasing processes.

The company's sustainability initiatives include eco-efficient operations, renewable energy adoption, and sustainable product development. Aptar is a member of the UN Global Compact, Ellen MacArthur Foundation, and World Business Council for Sustainable Development. The company has also received an 'A' score on CDP Climate Change assessment and was named among Barron's 100 Most Sustainable U.S. Companies.